Cargando…
Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?
The introduction of monoclonal antibodies (mAbs) to the treatment of inflammatory bowel disease (IBD) was an important medical milestone. MAbs have been demonstrated as safe and efficacious treatments of IBD. However, a large percentage of patients either fail to respond initially or lose response t...
Autores principales: | Strik, Anne S., Wang, Yow-Ming C., Ruff, Laura E., Yashar, William, Messmer, Bradley T., Mould, Diane R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364290/ https://www.ncbi.nlm.nih.gov/pubmed/30187153 http://dx.doi.org/10.1208/s12248-018-0257-y |
Ejemplares similares
-
Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology
por: Chatelut, Etienne, et al.
Publicado: (2021) -
A general process for the development of peptide-based immunoassays for monoclonal antibodies
por: Sanchez, Ana B., et al.
Publicado: (2010) -
Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?
por: Zheng, Songmao, et al.
Publicado: (2022) -
Therapeutic monoclonal antibody for sporotrichosis
por: Almeida, Sandro R.
Publicado: (2012) -
Therapeutic Applications of Monoclonal Antibodies
por: Berger, Mitchell, et al.
Publicado: (2002)